Skip to content

This pharma stock is gearing up for a huge surge

This pharma stock is gearing up for a huge surge
Elmaz Sabovic

After years of a slowdown in performance and revenue, Eli Lilly (NYSE: LLY) is starting to turn the page. With its innovations in the pharmaceutical sector, most notably in diabetes treatment, its medications performed well, raking in a huge chunk of revenue and propelling this pharmaceutical giant to the 10th largest company by market cap.

Eli Lilly’s latest pharmaceutical product for diabetes and obesity, Mounjaro (marketed as Zepbound for weight management), is anticipated to potentially emerge as the highest-selling therapy in the industry’s history.

Moreover, Eli Lilly possesses a significantly more diversified revenue stream. It maintains a diverse portfolio with several significant therapies in various fields in its development pipeline. Notably, it is awaiting approval for the Alzheimer’s disease treatment Donanemab, poised to achieve impressive status potentially.

Simultaneously, Lilly acquired Point Biopharma, a specialist in radioligand treatments for cancer. The company combines a radioisotope with a molecule designed to locate cancer cells within the body. This innovative approach enables the drug to administer focused radiation directly to the tumor, minimizing the impact on healthy tissue.

Technical analysis of LLY stock and analyst forecast

Technical indicators for LLY stock spell out a recommendation of ‘strong buy’ with a buy rating of 16, and moving averages agree at the rating of 13. Oscillators indicate a ‘buy’ at 3.

Technical analysis of LLY stock. Source: TradingView
Technical analysis of LLY stock. Source: TradingView

It seems that 26 analysts share a generally positive outlook for this stock, as 17 suggest a ‘strong buy,’ 3 are of the ‘buy’ opinion, 4 indicate a ‘hold,’ while one opted for a ‘sell,’ and another one suggested a ‘strong sell.’

Analysts’ LLY stock price target. Source: TradingView
Analysts’ LLY stock price target. Source: TradingView

The price target is an average of $648.33, indicating a further 3.14% increase from the current levels. And with the most optimistic target being set at $763, or 21.38% further gain.

LLY stock price analysis

At the time of press, LLY stock was trading at $628.58, indicating an increase of 0.84% since the previous closure, while losing -1.62% in the last five trading sessions.

LLY 24-hour stock price chart. Source: Finbold
LLY 24-hour stock price chart. Source: Finbold

Since the year commenced, this stock has added 6.14% to its value.

Only time will tell whether this company will continue its success with the latest medication and add to its innovations. It shows significant effort to stay ahead of its competition and remain the industry leader.

Buy stocks now with Interactive Brokers – the most advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.